About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AERI - Aerie Pharmaceutical...| Previous Close | $12.10 | Open | $12.49 |
| Volume | 2.42M | Market Cap | 562.27M |
| Yield | Last Dividend |
| Aerie Pharmaceuticals Reports Second Qua... | 08/06/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Announce Second... | 07/30/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals Appoints Peter J. ... | 06/11/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie (AERI) Up 1.9% Since Last Earnings... | 06/05/20 |
| Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Aerie Pharmaceuticals Reports First Quar... | 05/06/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Present at the ... | 05/05/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Announce First ... | 04/29/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals (AERI) Expected to... | 04/28/20 |
| Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key e... | |
| Aerie (AERI) Suspends Guidance Due to Co... | 04/13/20 |
| Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak. | |
| Aerie Pharmaceuticals Provides 2020 Comp... | 04/09/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals to Present at the ... | 04/07/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Why Is Aerie (AERI) Down 40.5% Since Las... | 03/21/20 |
| Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| The Daily Biotech Pulse: Mesoblast To Te... | 03/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) A... | |
| The Daily Biotech Pulse: GenMark Diagnos... | 03/03/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) ... | |
| Aerie Pharmaceuticals to Present at the ... | 02/24/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Stock Alert: Aerie Pharma (AERI) Catches... | 02/21/20 |
| Shares of Aerie Pharmaceuticals Inc. (AERI), a revenue-generating ophthalmic pharmaceutical company, are up more than 10%, following better-than-expec... | |
| Aerie Pharmaceuticals EPS misses by $0.1... | 02/20/20 |
| Aerie Pharmaceuticals (NASDAQ:AERI): Q4 Non-GAAP EPS of -$0.96 misses by $0.19; GAAP EPS of -$1.21 misses by $0.24. Revenue of $24.66M (+70.5% Y/Y) be... | |
| Aerie Pharmaceuticals Announces Appointm... | 02/18/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals Announces Appointm... | 02/03/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals Announces U.S. Foo... | 01/21/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie's (AERI) Application for Roclanda ... | 01/03/20 |
| European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda. | |
| Aerie Pharmaceuticals Announces Acceptan... | 01/02/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals Announces Appointm... | 12/09/19 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Present at the ... | 11/26/19 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| The Daily Biotech Pulse: Roche-Spark Dea... | 11/22/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.... | |
| Aerie Pharmaceuticals Receives European ... | 11/21/19 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie to Acquire Dry Eye Disease-Focused... | 11/19/19 |
| Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline. | |
| Aerie Pharmaceuticals Announces Agreemen... | 11/18/19 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (???Aerie???), an ophthalmic pharmaceutical company focused on the discovery,... | |
| Buy rating | 08/07/20 |
| Needham maintains Buy rating and lowers Price Target from $32.00 to $26.00 | |
| Strong Buy rating | 06/01/20 |
| Oppenheimer maintains Outperform rating and raises Price Target from $22.00 to $24.00 | |
| Date | 2020-08-06 (AMC) | Est. (EPS/Rev.) | ($0.80)/ 17.45M |
| Actual (EPS/Rev.) | $-1.05/ $18.03 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Small Cap Trader | James Bills | 41.00 % | Follow |
| Symmetry Options | Symmetry Options | 33.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
| OptionAdvantage | OptionAdvantage | 0.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
